15
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Fezolinetant for VMS: a balanced view on efficacy and safety needed

ORCID Icon, &
Received 16 May 2024, Accepted 18 Jun 2024, Published online: 09 Jul 2024
 

Disclosure statement

J. Douxfils reports personal fees from Daiichi-Sankyo, Diagnostica Stago, Gedeon Richter, GyneBio Pharma, Mithra Pharmaceuticals, Norgine, Roche, Roche Diagnostics, Technoclone, Werfen and YHLO, outside the submitted work. All other authors declare no competing interests.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 277.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.